Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Research & Development (2016 - 2025)

Syndax Pharmaceuticals has reported Research & Development over the past 9 years, most recently at $10.0 million for Q1 2025.

  • Quarterly results put Research & Development at $10.0 million for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $29.0 million (changed N/A YoY), and the annual figure for FY2025 was $258.8 million, up 7.09%.
  • Research & Development for Q1 2025 was $10.0 million at Syndax Pharmaceuticals, down from $15.0 million in the prior quarter.
  • Over the last five years, Research & Development for SNDX hit a ceiling of $15.0 million in Q3 2024 and a floor of $2.0 million in Q1 2021.
  • Median Research & Development over the past 3 years was $6.0 million (2021), compared with a mean of $7.2 million.
  • Peak annual rise in Research & Development hit 79.08% in 2021, while the deepest fall reached 86.12% in 2021.
  • Syndax Pharmaceuticals' Research & Development stood at $2.0 million in 2021, then soared by 650.0% to $15.0 million in 2024, then tumbled by 33.33% to $10.0 million in 2025.
  • The last three reported values for Research & Development were $10.0 million (Q1 2025), $15.0 million (Q3 2024), and $2.0 million (Q3 2021) per Business Quant data.